EOLS
(NASDAQ)
4.88
-0.0495  (-1.01%)
Volume (24h): 12,959.00 Day Range: 4.88 - 4.88
Market Cap: 164.60M 52W Range: 3.12 - 20.27
May-25-20 09:40AM Evolus Volatility Remains A Mystery, Analyst Highlights Stock’s Unique PotentialTipRanks
May-14-20 01:50PM What You Need To Know About The Evolus, Inc. (NASDAQ:EOLS) Analyst Downgrade TodaySimply Wall St.
May-12-20 09:00AM Evolus, Inc. (EOLS) Q1 2020 Earnings Call TranscriptMotley Fool
May-11-20 08:01PM Evolus Reports First Quarter 2020 Results and Provides Business UpdateGlobeNewswire
May-06-20 08:01PM Evolus to Report First Quarter 2020 Financial Results and Provide a Business Update on Monday, May 11, 2020GlobeNewswire
Apr-16-20 08:52PM Evolus Provides Strategic Business UpdateGlobeNewswire
Apr-05-20 01:55PM Time To Worry? Analysts Are Downgrading Their Evolus, Inc. (NASDAQ:EOLS) OutlookSimply Wall St.
Mar-05-20 01:05PM The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19Benzinga
Mar-04-20 02:08PM Evolus Provides Update on International Trade Commission (ITC) CaseGlobeNewswire
Mar-03-20 02:00PM Evolus to Participate in Barclays 2020 Global Healthcare ConferenceGlobeNewswire
Feb-28-20 01:43PM Implied Volatility Surging for Evolus (EOLS) Stock OptionsZacks
Feb-25-20 12:00PM Evolus Reports Fourth Quarter and Full Year 2019 Results and Provides Business UpdateGlobeNewswire
11:00AM Evolus, Inc. to Host Earnings CallACCESSWIRE
Feb-13-20 01:30PM Evolus to Participate in 9th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswire
Feb-12-20 01:30PM Evolus to Report Fourth Quarter and Full Year 2019 Financial Results and Provide a Business Update on Tuesday, February 25, 2020GlobeNewswire
Jan-27-20 04:17PM 3 Healthcare Stocks That Offer a Compelling Buying OpportunityTipRanks
02:00PM Positive Results from Phase III, Split-Face, Head-to-Head Study Comparing OnabotulinumtoxinA and PrabotulinumtoxinA in the Treatment of Crow’s Feet Lines Published in Dermatologic SurgeryGlobeNewswire
Jan-09-20 02:00PM Evolus Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 RevenueGlobeNewswire
Jan-06-20 11:25AM Need To Know: Evolus, Inc. (NASDAQ:EOLS) Insiders Have Been Buying SharesSimply Wall St.
Dec-17-19 09:38PM Is Evolus, Inc. (EOLS) A Good Stock To Buy?Insider Monkey
Nov-07-19 09:10PM Evolus to Participate in Stifel Healthcare ConferenceGlobeNewswire
11:50AM What Kind Of Shareholder Owns Most Evolus, Inc. (NASDAQ:EOLS) Stock?Simply Wall St.
Nov-07-19 06:18AM Evolus Announces Pricing of Public Offering of Common StockGlobeNewswire
Nov-06-19 09:02PM Evolus Announces Proposed Public Offering of Common StockGlobeNewswire
Nov-04-19 12:00PM Evolus Reports Third Quarter 2019 Financial Results and Provides Business UpdateGlobeNewswire
Oct-31-19 06:13PM Hedge Funds Have Never Been This Bullish On Evolus, Inc. (EOLS)Insider Monkey
Oct-28-19 08:05PM Evolus to Report Third Quarter 2019 Financial Results and Provide a Business Update on Monday, November 4, 2019GlobeNewswire
Oct-16-19 01:05PM Evolus and Clarion Medical Technologies Announce First Shipment of Nuceiva™ (prabotulinumtoxinA) to Customers in CanadaGlobeNewswire
Oct-15-19 09:04PM Allergan (AGN) Shareholders Approve Acquisition by AbbVieZacks
Oct-01-19 01:09PM Evolus Receives Approval for Nuceiva™ in the European UnionGlobeNewswire
Sep-27-19 11:14AM Market Sentiment Around Loss-Making Evolus, Inc. (NASDAQ:EOLS)Simply Wall St.
Sep-18-19 01:00PM Evolus will Participate in Cantor Global Healthcare ConferenceGlobeNewswire
Sep-04-19 10:00AM Evolus Announces Successful Completion of the Jeuveau® Experience Treatment (J.E.T) ProgramGlobeNewswire
Aug-22-19 08:05PM Evolus to Participate in Two Upcoming Investor ConferencesGlobeNewswire
Aug-20-19 03:20PM Is Evolus (NASDAQ:EOLS) Weighed On By Its Debt Load?Simply Wall St.
Aug-13-19 12:02PM Evolus Could See Breakout SoonTheStreet.com
Aug-12-19 03:23PM Evolus, Inc. (EOLS) Q2 2019 Earnings Call TranscriptMotley Fool
11:59AM UPDATE 1-Evolus reports sales of its Botox rival ahead of expectationsReuters
Aug-12-19 11:01AM Evolus says launch of its Botox rival ahead of its expectationsReuters
11:01AM Evolus Reports Second Quarter 2019 Financial ResultsGlobeNewswire
Aug-09-19 11:36AM What's in Store for Flexible Solutions (FSI) in Q2 Earnings?Zacks
Aug-08-19 11:03AM Barrick (GOLD) to Post Q2 Earnings: What's in the Cards?Zacks
10:39AM Advance Auto Parts (AAP) to Post Q2 Earnings: What's Up?Zacks
Aug-01-19 12:30PM Evolus to Report Second Quarter 2019 Financial Results and Provide a Business Update on Monday, August 12, 2019GlobeNewswire
Jul-30-19 02:22PM 4 Medical Product Stocks Set to Beat This Earnings SeasonZacks
Jul-15-19 12:30PM Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D.GlobeNewswire
Jul-12-19 12:39PM Will Evolus Continue to Surge Higher?Zacks
Jul-10-19 11:09AM Evolus Is Shaping Up Nicely, Time to Go LongTheStreet.com
Jul-08-19 01:41PM AbbVie (ABBV) Shares Down So Far This Year: Here's WhyZacks
Jul-01-19 04:49PM Who Has Been Buying Evolus, Inc. (NASDAQ:EOLS) Shares?Simply Wall St.
Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)